July 2018 – Maas Biolab

Helmuth von Moltke Elected to Maas Biolab Board

maasbiolab
July 2, 2018
2018
0 Comments

Santa Fe, N.M. --- July 2, 2018 ---Maas Biolab, LLC has announced that Helmuth von Moltke has been elected to the Maas Biolab Board of Managers for a new term after having previously served from the inception of the company until 2012. Mr. von Moltke is one of the nine founders of…

Maas Biolab Twitter FeedFollow

Maas Biolab @MaasBiolab·

30 Jul

FDA Fast Tracks Traumatic Brain Injury Drug, NeuroSTAT®, From NeuroVive Pharmaceuticals-Shares Jump 55%, Volume 45 Million - https://t.co/SSA6IN0nIE

Reply on Twitter Retweet on Twitter1 Like on Twitter Twitter

Maas Biolab @MaasBiolab·

30 Jul

NEVPF stock uptick appears to be in response to Saturday press release of FDA FAST TRACK status for NeuroSTAT, drug for severe traumatic brain injury. NeuroSTAT has Orphan status for TBI in both Europe and the USA, and has had positive Phase 2 trial results.

Reply on Twitter Retweet on Twitter Like on Twitter Twitter

Maas Biolab @MaasBiolab·

30 Jul

NeuroVive Pharmaceutical, dual listed Swedish NASDAQ and American OTCQX (symbol NEVPF) has another rise of share price of 22% today (55% yesterday), very high volume of 41 million shares, half way through the Swedish trading day.

Reply on Twitter Retweet on Twitter1 Like on Twitter Twitter

Retweet on Twitter Maas Biolab Retweeted

Marcus Keep @MarcusKeep·

25 Mar

#mdpicells 2,4 Dinitrophenol as Medicine https://t.co/l2E83auAmx @MDPIOpenAccess
Mitochondrial medication: Dr. John Geisler's tour de force encyclical for 2,4 DNP to treat neurologic and mitochondrial diseases. Download the Cells free-access publication, and read!

Reply on Twitter Retweet on Twitter1 Like on Twitter1 Twitter

Retweet on Twitter Maas Biolab Retweeted

LREsystem Ltd @LREsystem·

1 Feb

It's back! the first of the new LRE system procedure undertaken in Ypres, Belgium.
LREsystem Ltd, bringing more power to your elbow by restoring elbow anatomy. Do not remove bone, instead, resurface, realign and restore the normal anatomy to remove all pain.

Reply on Twitter Retweet on Twitter2 Like on Twitter1 Twitter

Maas Biolab @MaasBiolab·

15 Nov

NeuroVive Receives Vinnova Funding to Support Development of NV354: https://t.co/tqLc3eOtzW

Reply on Twitter Retweet on Twitter Like on Twitter Twitter

Maas Biolab @MaasBiolab·

10 Oct

NeuroVive Receives KL1333 Clinical Trial Regulatory Approval: https://t.co/rhM2e2fB7X

Reply on Twitter Retweet on Twitter Like on Twitter Twitter

Maas Biolab @MaasBiolab·

4 Oct

NeuroVive reports first NeuroSTAT clinical efficacy signal in traumatic brain injury (TBI): https://t.co/Yrt4i54q5z

Reply on Twitter Retweet on Twitter Like on Twitter Twitter

Maas Biolab @MaasBiolab·

6 Sep

NeuroVive Receives Positive FDA Feedback on its NeuroSTAT TBI Development Plan: https://t.co/rFHVtH8C5e

Reply on Twitter Retweet on Twitter Like on Twitter Twitter

Maas Biolab @MaasBiolab·

28 Aug

NeuroVive’s NVP015 program will be accelerated through award of major research grant to Children’s Hospital of Philadelphia: https://t.co/lHuixW86VK

Reply on Twitter Retweet on Twitter Like on Twitter1 Twitter